1-(5-Bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate

Catalog No. :
ACZIPE154
CAS No. :
2816108-46-8
Molecular Formula :
C10H12BrF2NO4S
Molecular Weight :
360.18

IUPAC Name:1-(5-bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate

1-(5-Bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$90.00Login to see priceIn stockInquiry
100mg98%$152.00Login to see priceIn stockInquiry
250mg98%$258.00Login to see priceIn stockInquiry
1g98%$693.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(5-Bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate
IUPAC Name1-(5-bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate
Molecular FormulaC10H12BrF2NO4S
Molecular Weight360.18
SMILESCS(=O)(OC(C1=NC=C(Br)C=C1)CCOC(F)F)=O
InChI KeyKRJISBZVZGIMNG-UHFFFAOYSA-N
Synonym1-(5-Bromopyridin-2-yl)-3-(difluoromethoxy)propyl methanesulfonate;2-Pyridinemethanol, 5-bromo-α-[2-(difluoromethoxy)ethyl]-, 2-methanesulfonate
CAS No.2816108-46-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACZIPE154 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZIPE154 route product structure diagram
    ACZIPE1542816108-46-8 In Stock
Inquiry

2. ACZIPE154 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZIPE154 route product structure diagram
    ACZIPE1542816108-46-8 In Stock
Inquiry

Comments (0)